Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy

Stephanie Gaillard, Jason B. Dinoso, Julia A. Marsh, Amy E. DeZern, Karen A. O'Connell, Adam M. Spivak, Karla Alwood, Christine M. Durand, Richard F. Ambinder, Joel N. Blankson

Research output: Contribution to journalArticle

Abstract

The mechanism of elite control of HIV-1 replication is not fully understood. While immunosuppression due to rituximab based chemotherapy has been associated with increased replication of HBV, CMV, and HIV-1, control of replication-competent HIV-1 was maintained in an elite controller/suppressor treated with a regimen that included vincristine, cyclophosphamide, prednisone, four rounds of plasmapheresis and ten cycles of rituximab. The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients.

Original languageEnglish (US)
Pages (from-to)195-198
Number of pages4
JournalJournal of Clinical Virology
Volume51
Issue number3
DOIs
StatePublished - Jul 1 2011

Keywords

  • Elite controllers
  • Elite suppressors
  • HIV
  • Neutralizing antibody
  • Rituximab

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy'. Together they form a unique fingerprint.

  • Cite this